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ABSTRACT
Radiation therapy is a major primary treatment option for both localized early 
stage prostate cancer, and for advanced, regionally un-resectable, cancer. However, 
around 30% of patients still experience biochemical recurrence after radiation therapy 
within 10 years. Thus, identification of better biomarkers and new targets are urgently 
required to improve current therapeutic strategies. The miR-99 family has been shown 
to play an important role in the regulation of the DNA damage response, via targeting 
of the SWI/SNF chromatin remodeling factors, SMARCA5 and SMARCD1 in cell line 
models. In the present study, we have demonstrated that low expression of miR-99a 
and miR-100 is present in cell populations which are relatively radiation insensitive, 
for example in prostate cancer stem cells and in castration-resistant prostate cancer. 
Additionally, treatment of cells with the synthetic glucocorticoid, Dexamethasone 
resulted in decreased miR-99a and 100 expression, suggesting a new mechanism 
of miR-99a and 100 regulation in androgen-independent prostate cells. Strikingly, 
treatment of prostate cells with the glucocorticoid receptor inhibitor, Mifepristone was 
found to sensitize prostate cells to radiation by increasing the levels of miR-99a and 
miR-100. These results qualify the miR99 family as markers of radiation sensitivity 
and as potential therapeutic targets to improve efficiency of radiotherapy.
INTRODUCTION
Radiation therapy (RT) is a major primary treatment 
option for localized early stage prostate cancer (PCa) and 
regionally un-resectable advanced PCa [1, 2]. Recently there 
have been significant improvements to RT methodology, 
resulting in an increase of recurrence-free survival 
[3]. However, around 30% of patients still experience 
biochemical recurrence after RT within 10 years, for which 
there is no consensus regarding optimal management [4]. 
One of the main causes of the varied response to RT is the 
high inter- and intra-tumoral heterogeneity found in PCa [5, 
6]. Moreover, this heterogeneity is primarily responsible for 
the current lack of markers to group patients into high- and 
low-risk for relapse, which consequently results in over-
treatment of 20–42% of patients [7].
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Several studies have demonstrated that a small 
population of primitive stem-like cells (cancer stem cells; 
CSC) within the tumor are more resistant to radiotherapy 
than the majority of cells, and are directly responsible 
for tumor recurrence [8, 9]. In PCa, cell populations with 
the CD44+/α2β1integrin
hi/CD133+, CD49fhi/Trop2hi, and 
CD44+/CD49fhi/Trop2+ phenotype have been shown to 
share CSC properties [10–14]. However, these markers 
have not been used to stratify patients on the basis of their 
radiosensitivity.
MicroRNAs (miRNAs) have demonstrable potential 
as diagnostic, predictive, and prognostic markers, and 
may provide a promising new class of therapeutic targets 
[15–17]. MiRNAs are small 17–25 nucleotide non-coding 
RNA molecules, which regulate post-transcriptional 
gene expression in a sequence-specific manner and have 
a central role in multiple biological functions, including 
cell survival, proliferation, and DNA damage responses 
[18–20]. Several miRNAs can share a nearly identical 
seed sequence and are likely to target the same sets of 
mRNAs. These miRNAs have been grouped together in 
“miRNA families”. The miR-99 family (miR-99a, miR-
99b, and miR-100) has been reported to be upregulated 
following DNA damage, and their expression has been 
correlated with radiation sensitivity, in breast and PCa 
cell lines, by their ability to downregulate the chromatin 
remodeler SWI/SNF-related, matrix-associated, actin-
dependent regulator of chromatin (SMARC) A5 (SNF2H) 
[21]. Thus, induction of the members of the miR-99 family 
represents a switch by which cells subjected to multiple 
rounds of radiation might be sensitized to RT. The precise 
molecular mechanism by which RT induces cell death has 
not been defined, however a failure to repair DNA damage 
seems to be one of the main causes [22]. Although RT 
is a predominant front-line treatment, it is also known 
to cause several side effects (including pain, fatigue and 
sexual, urinary and bowel dysfunction) which have a 
detrimental effect on quality of life [23]. Therefore, in 
order to effectively manage RT-side effects, a lower dose 
of radiation, optimized to achieve the same results, would 
be an ideal therapeutic strategy.
This study shows, for the first time the role of two 
members of the miR-99 family (miR-99a and miR-100) 
in DNA damage repair following radiation in primary 
PCa cell models, and provides additional functional and 
mechanistic details about the miR-99a family-DNA repair 
relationship. These miRNAs are expressed at only low 
levels in the stem-like RT-resistant CD44+/α2β1integrin
hi/
CD133+ subpopulations from benign and cancerous 
prostate tissue, supporting their role in treatment resistance 
and cancer relapse [8]. In addition, we show that miR-99a 
and miR-100-mediated radiation-sensitivity is influenced 
by inhibition of the Glucocorticoid receptor (GR, NRC1), 
revealing a potential new treatment strategy to improve 
radiotherapy and reduce PCa relapse.
RESULTS
Lower expression of miR-99a and miR-100 is 
associated with aggressive PCa and a stem cell-
like phenotype
Analysis of our published miRNA expression array 
data demonstrates that the miR-99 family members, 
miR-99a and miR-100 (miR-99a/100), are significantly 
suppressed in prostate stem-like cells (SC) compared to 
their differentiated progeny; committed basal (CB) cells 
(Figure 1A, 1B) [24, 25]. This was true for SCs and 
CBs enriched from benign prostatic hyperplasia (BPH), 
treatment naïve PCa (tnCancer), and castration-resistant 
PCa (CRPC) samples. Analysis of two further expression 
arrays published by other groups revealed that miR-99a 
and miR-100 are also significantly suppressed in primary 
tumors compared to benign samples (Figure 1C, 1D) [26, 
27]. Interestingly, data from Taylor et al (2012) showed 
that the expression of these two miRNAs is further 
suppressed in metastatic PCa samples compared to 
treatment naïve cancers (P<0.001) (Figure 1D). These data 
are consistent with other large-scale sequencing studies, 
which have also reported a decrease of the miR-99 family 
in PCa [28–30]. Although levels exhibit no correlation 
with Gleason grade (Supplementary Figures S1A, S1B), 
Kaplan- Meier survival analysis on the Taylor et al data 
showed that lower expression of miR-99a/100 is associated 
with poorer survival (Figure 1E, 1F). Additionally, miR-
99a/100 were also found to be significantly co-expressed 
in prostate samples (Pearson: 0.07485, p<0.0001) (Figure 
1G). In support of these findings we observed that in 
patient-derived epithelial cells, miR-99a/100 expression 
was significantly suppressed in CRPC compared to benign 
disease and tnCancer (P<0.01) (Figure 1H). Quantitative 
real time polymerase chain reaction (qRT-PCR) analysis of 
commonly used cell lines showed that more tumorigenic 
PCa cell lines, such as DU145 and 22Rv1, had a lower 
expression of the miR-99 family than less tumorigenic 
PCa cell lines, e.g. LNCaP (Figure 1I). Taken together, 
these data suggest that miR-99a/100 function together, and 
that their lower expression imparts aggressive PCa disease 
and a stem cell-like phenotype in a variety of human PCa 
models.
Suppression of miR-99a and miR-100 promotes 
efficient DNA repair in cells with high miR-
99a/100 expression
A previous study showed that higher expression of 
the miR-99 family correlated with radiation sensitivity of 
prostate cell lines [21]. Cell viability assays revealed that 
the radiation sensitivity of the tested PCa cell lines (Figure 
2A) is higher in cells with low expression of the miR-99 
family (Figure 1I). Furthermore, inhibition of miR-99a/100 
in LNCaP cells (Supplementary Figure S1D) increases 
Oncotarget3www.impactjournals.com/oncotarget
Figure 1: miR-99a/100 function together and their lower expression imparts aggressive PCa disease and stem cell-like 
phenotype. A+B. Expression profiles of miR-99a (A) and miR-100 (B) in the separated populations: stem cell (SC), cancer stem cell 
(CSC), transit amplifying (TA) and committed basal (CB) (n=5 Benign prostatic hyperplasia (BPH) and treatment naïve Prostate Cancer 
(tnCancer), n=3 castration resistant PCa (CRPC). C+D. miR-99a and miR-100 levels in unseparated benign and malignant populations 
from the GSE21036 (C, benign n=28, malignant n=99, metastasis n=14) and GSE36802 (D, benign n=21, malignant n=21) data sets. 
E+F. Survival analysis from GSE21036 of patients with low and high mir-99a (E) and miR-100 (F) levels using the Project Betastasis 
database (http://www.betastasis.com/prostate_cancer/taylor_et_al_2010/kaplan-meier_survival_plot/28/02/2016). The median was chosen 
as threshold. G. Correlation analysis of miR-99a and miR-100 after pooling the expression data of GSE21036 and GSE36802. The analysis 
shows a significant correlation between miR-99a and miR-100 expression in PCa patients. H. Comparison of miR-99 and miR-100 
expression in unfractionated primary prostate samples from BPH (n=3), tnCancer (n=3) and CRPC (n=3). I. Expression profiles of miR-99 
and miR-100 in prostate cancer cell lines (n=3). Data are expressed as mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s ttest).
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radioresistance (Figure 2B). To further investigate the role 
of miR-99a/100 in radiation response, we inhibited miR-
99a or miR-100 expression in highly expressing BPH and 
PCa-derived primary CB cells (Figure 2C). Inhibition of 
miR-99a/100 resulted in a growth advantage (Figure 2D), 
and we observed a significant (~2-fold) increase in colony 
forming efficiency following exposure to 5 Gy radiation 
(Figure 2D, 2E).
Suppression of miR-99a/100 promotes 
recruitment of DNA repair proteins
Since our results showed that inhibition of miR-
99a/100 expression led to a faster recovery of CB cells 
after irradiation (Figure 2D, 2E), we next quantified 
levels of DNA damage in CB cells with or without miR-
99a/100 inhibition. Nuclear pATM/ATR substrate and 
phosphorylated p53 levels were measured 15 min after 
exposure to 5 Gy radiation (Figure 3A), but the number 
of cells with >5 foci did not change. To elucidate the 
mechanism(s) behind the role of miR-99a/100 in DNA 
repair, we investigated the potential roles of chromatin 
remodeling and DNA repair proteins. Increased 
phosphorylation of histone H2AX at serine 139 (γH2AX) 
has previously been reported as the most sensitive marker 
of DNA damage, where decreased phosphorylation reflects 
subsequent repair of the DNA lesion [31]. To monitor 
damage and repair of the DNA, the number of γH2AX 
foci per cell, after irradiation of miR-99a/100 inhibited CB 
cells were estimated by immunofluorescence. Under all 
conditions γH2AX peaked at the same level in the first 
30 min post-irradiation, but 215 min after irradiation, the 
cells transfected with miR99a/100 inhibitors showed a 
50% decrease in the number of γH2AX foci. Scrambled 
controls failed to achieve this 50% decrease until 360 
min post-irradiation (Figure 3B). This finding, combined 
with the earlier observation that these cells recover faster 
after irradiation, led us to formulate the hypothesis that 
DNA damage is repaired more rapidly after miR-99a/100 
inhibition. Assessment of the total pixel intensity of 
the nuclear chromatin accessibility marker, Histone 3 
acetylation (H3ac), after 30 min, showed an increased 
histone H3ac after miR-99a/100 inhibition (Figure 3C). 
Using the same technique, we observed a significant 
increase in the DNA damage sensors BRCA1 and RAD51 
in miR-99a/100- inhibited cells 2-hours after exposure to 
5Gy irradiation (Figure 3D). In support of our findings, 
phosphorylation of the damage sensor protein p53, and 
Figure 2: Suppression of miR-99a and miR-100 promotes efficient DNA repair in cells with high miR-99a/100 
expression. A. Proliferation assays showing the relative surviving fraction of PCa cell lines 48 h after exposing them to 2, 5, and 10 Gy 
radiation (n=3). B. Proliferation assays showing the relative surviving fraction of LNCaP cells transfected with control, miR-99a-inhibitor, 
and miR-100-inhibitor cells 48 h after exposing the to 2, 5, 10 Gy radiation (n=3). C. Schematic representation of methodology for miRNA 
inhibition experiments. Committed basal (CB) cells, which express relatively high levels of miR-99a/100, were transfected with control, 
miR-99a-inihibitor or miR-100 inhibitor for 3 days and then analyzed with or without exposure to 5-Gy radiation. D. Proliferation of 
malignant irradiated CB cells measured by live cell count after miR-99a and miR-100 inhibition (n=3 PCa). E. Colony forming assay of 
malignant irradiated CB cells after miR-99a and miR-100 inhibition (n=3 PCa). Data are expressed as mean ± s.d. *P < 0.05, **P < 0.01, 
***P < 0.001 (Student’s ttest).
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Figure 3: Suppression of miR-99a and 100 promotes DNA repair enhance recruitment of DNA repair proteins. A. 
Quantification of positive nuclear phospho-ATM/ATR substrate and phospho-P53 (s-20) stained CB cells transfected with miR-99a and 
100 inhibitor. Immunofluorescence staining was performed was performed 30 minutes after exposure to 5-Gy (n=3 PCa, each sample in 
triplicate), >250 cells/sample were counted. B. Quantification of γH2AX immunofluorescence foci/nucleus at multiple time points after 
transfection of miR-99a/100 inhibitor in CB cells following 5-Gy radiation exposure (n=3 PCa, each sample in triplicate), >250 cells/sample 
were counted. Line represents 50% of total γH2AX foci/cell. C. Quantification of nuclear pan-histone 3-acetylation immunofluorescence 
staining intensity by Velocity Quantitation software in miR-99a and 100-inhibitor transfected CB cells 30 minutes after exposure to 5-Gy 
radiation (n=3 PCa). n indicates total number of cells included in the analysis. D. Quantification of miR-inhibitor transfected CB cells 
exhibiting nuclear BRCA1 and RAD51 immunofluorescence foci, 120 minutes after exposure to 5-Gy radiation (n = 3 PCa, each sample 
in triplicate), >250 cells/sample were counted. E. Representative pictures of immunofluorescence staining for phosphop53 (s-20), cleaved 
caspase 3, and cleaved PARP expression in miR-99a/100 inhibitor transfected CB cells, 24 h after exposure to 5-Gy radiation (n=3 PCa, 
each sample in triplicate). The right panel shows quantitation of staining using Velocity Quantitation software. n indicates total number of 
cells quantified. Scale bar: 120 μm. Data are expressed as mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s ttest).
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of the apoptotic markers cleaved caspase 3 and cleaved 
PARP, both showed a significant decrease in cells exposed 
to miR-99a/100 inhibition 24 h after irradiation (Figure 
3E). These data provide further evidence that lower 
expression of miR-99a/100 permits efficient DNA repair, 
whilst expression of miR-99a/100 induces p53-dependent 
apoptosis following DNA damage.
miR-99a/100 inhibition-dependent DNA repair is 
mediated by SMARCA5 and SMARCD1
SMARCA5 and SMARCD1 are major components 
of the SWI/SNF chromatin remodeling complex, both 
of which play essential roles in DNA damage repair 
and cell survival post-DNA damage [32]. Luciferase 
3’UTR-studies using PCa cell lines have shown that 
SMARCA5 can be regulated by miR-99a/100 and 
influences proliferation, PSA protein levels and repair 
of double-strand DNA breaks [21, 30]. Using primary 
PCa cells, we investigated this relationship in detail to 
obtain more mechanistic data in the context of cancer 
stem cells. As reported in other systems, SMARCA5 and 
SMARCD1 proteins were upregulated (Figure 4A) after 
inhibition of miR-99a/100 [21, 30]. Since SMARCA5 
is known to be rapidly recruited at DNA damage sites 
in the nucleus [33], we measured post-radiation nuclear 
SMARCA5 and SMARCD1 accumulation in CB cells, 
using immunofluorescence. Both proteins reached their 
highest nuclear levels after 3 minutes and began to decline 
after 5 min (Supplementary Figure S2A). Accordingly, 
nuclear SMARCA5 and SMARCD1 levels were measured 
in miR-99a/100 inhibited CB populations 5 min after 
irradiation. miR-99a/100 inhibited CB cells showed 
significantly higher nuclear SMARCA5 and SMARCD1 
accumulation compared with scrambled miRNA 
transfected cells (Figure 4B). Similarly, the low miR-
99a/100 expressing SC fraction accumulated significantly 
higher levels of the SMARCA5 and SMARCD1 in the 
nucleus, compared with the high miR-99a/100 expressing 
CB population after radiation exposure (Supplementary 
Figure S2B). Therefore, miR-99a/100 influences DNA 
repair via regulation of SMARCA5 and SMARCD1, 
even in primary PCa cells. To further validate this, we 
attempted to reverse the efficient DNA repair ability 
acquired by CB cells, due to inhibition of miR-99a, by 
simultaneously knocking down expression of SMARCA5 
or SMARCD1. Simultaneous inhibition of SMARA5/
SMARCD1 and miR-99a reduced the post-radiation 
colony recovery ability of CB cells (Figure 4C). CB cells 
transfected with miR-99a inhibitor showed an increase in 
chromatin relaxation by increasing H3-acetylation (Figure 
4D), resulting in efficient nuclear recruitment of BRCA1 
and RAD51 (Figure 3D, 4E). Simultaneous inhibition 
of SMARCA5 and miR99-a, but not of SMARCD1, 
reduced H3-acetylation suggesting that miR-99a mediated 
chromatin relaxation is predominantly mediated by 
SMARCA5 only. Similarly, concurrent miR-99a inhibition 
and SMARCA5/SMARCD1 knock-down abrogated 
efficient BRCA1 and RAD51 nuclear recruitment at the 
DNA damage sites (Figure 4E). These molecular and 
functional readouts revealed that miR-99a/100 regulate 
SMARCA5 and SMARCD1 in primary PCa cells to 
enable DNA repair.
SMARCA5 and SMARCD1 mediated DNA 
repair is dependent on PARP1
Previous studies have shown that poly ADP 
ribose polymerase (PARP)1 is essential for SMARCA5 
recruitment at double-strand DNA break sites in the 
human osteosarcoma cell line U-2 OS [34]. We have 
previously shown that CSCs are more radioresistant than 
CB cells and PARP1 is specifically overexpressed in 
CSCs (Supplement Figure S2C) [8, 35]. Therefore, we 
further hypothesized that PARP proteins play an essential 
role in recruitment of SMARCA5 and SMARCD1 at 
DNA break sites in primary prostate cells. To inhibit 
PARP activity, the non-specific PARP activity inhibitor, 
nicotinamide and PARP1 endoribonuclease-prepared 
siRNA (esiRNA) were used [36]. When CB cells, where 
miR-99a expression was inhibited, were treated with 15 
μM nicotinamide, for 12 hours, and then irradiated with 
5Gy radiation, we observed that the post-radiation nuclear 
accumulation of SMARCA5/SMARCD1 was significantly 
reduced (Figure 4F). A similar reduction in SMARCA5/
SMARCD1 post-radiation nuclear localization was also 
observed when CB cells were co-transfected with miR-99a 
inhibitors and esiPARP1 (Figure 4G). PARP1 inhibition 
ultimately negated the post-radiation survival advantage 
imparted by miR-99a inhibition in CB cells (Figure 4H), 
suggesting that PARP1 is required for post-radiation 
nuclear accumulation of SMARCA5.
Suppression of miR-99a/100-induced efficient 
DNA repair in CB cells is not due to epithelial–
mesenchymal transition or de-differentiation
It is well established that cells undergoing epithelial-
mesenchymal transition (EMT) and SCs are more 
radioresistant [37, 38]. Lower expression of miR-99a/100 
and higher expression of SMARCA5/SMARCD1, and 
even PARP1 have all been associated with EMT and the 
stem cell phenotype in various other tissue types [39–45]. 
We therefore investigated whether induction of DNA 
repair via the miR-99a/100-SMARA5/SMARCD1 axis 
was due to either EMT or de-differentiation of CB cells 
into SC. We inhibited miR-99a/100 in CB cells and looked 
for EMT or dedifferentiation, using commonly used EMT 
and previously reported PCa and normal stem cell markers 
[10, 11, 35, 46–48]. None of these markers showed any 
changes after inhibition of miR-99a/100 (Figure 5A, 5B, 
5C). Colony forming efficiency is often used as a surrogate 
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Figure 4: Effects of miR-99a and 100 on DNA repair processes are regulated by SMARCA5 and SMARCD1. A. 
Representative western blot analysis of SMARCA5 and SMARCD1 expression in miR-inhibitor transfected malignant CB cells. B. 
Immunofluorescence staining for nuclear SMARCA5 and SMARCD1 in miR-99a and 100-inhibitor transfected CB cells, 5 minutes 
after exposure to 5-Gy radiation (n=5 PCa). Scale bar: 100 uM. Right panel shows the quantification of SMARCA5 and SMARCD1 
positive CB cells, >250 cells/sample counted and SMARCA5 and SMARCD1 fluorescence quantification using Velocity quantitation 
software. C. Colony forming experiments of CB cells transfected simultaneously with miR-99a inhibitor and SMARCA5 or SMARCD1 
endoribonuclease-prepared siRNA (esiRNAs) following 5-Gy radiation show a rescue of the effects mediated by miR-99a inhibitor alone 
(n=5 PCa, each sample is in triplicate). D. Quantification of nuclear pan-histone 3-acetylation immunofluorescence staining by Velocity 
Quantitation software in miR-99a inhibitor and SMARCA5 or SMARCD1 esiRNAs transfected CB cells. Immunofluorescence staining 
was performed 30 minutes after exposure to 5-Gy radiation (n=3 PCa, each sample in triplicate). n indicates total number of cells included 
in quantification analysis. E. Quantification of nuclear BRCA1 and RAD51 in CB cells simultaneously transfected miR-99a inhibitor 
and SMARCA5 or SMARCD1 esiRNA. Immunofluorescence staining was performed 120 minutes after exposure to 5-Gy radiation (n=3 
PCa, each sample in triplicate), >250 cells/sample were counted. F. Quantification of nuclear SMARCA5 and SMARCD1 in CB cells 
simultaneously transfected with miR-99a inhibitor and treated with or without the PARP1 inhibitor nicotinamide. Immunofluorescence 
staining was performed 120 minutes after exposure to 5-Gy radiation (n=5 PCa, each sample in triplicate), >250 cells/sample were counted. 
G. Quantification of nuclear SMARCA5 and SMARCD1 in CB cells simultaneously transfected with miR-99a inhibitor and PARP1 
esiRNA. Immunofluorescence staining was performed 120 minutes after exposure to 5-Gy radiation (n=5 PCa, each sample in triplicate), 
>250 cells/sample were counted. H. Colony forming experiments of CB cells transfected with SCRMBL or PARP1 esiRNA or treated with 
nicotinamide following by 5-Gy radiation showing a rescue of the effects mediated by miR-99a inhibitor alone (n=5 PCa, each sample in 
triplicate). Data are expressed as mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s ttest).
Oncotarget8www.impactjournals.com/oncotarget
to functionally assess stem-ness. Inhibition of miR-
99a/100 inhibition produced only a modest, but significant, 
increase in colony forming efficiency of CB cells (Figure 
5D). Moreover a scratch assay demonstrated that miR-
99a/100 inhibited CB cells did not increase their migratory 
potential (Figure 5E), an attribute of mesenchymal-like 
cells. These data provide multiple strands of evidence that 
miR-99a/100 inhibition in CB cells did not undergo EMT 
not de-differentiation, as a basis for radiation resistance.
Glucocorticoids upregulates miR-99a/100 
expression levels
We have previously shown that androgen regulated 
genes in luminal cells can also be controlled by a different 
steroid hormone in androgen-independent basal cells 
[48]. A previous study suggested that miR-99a/100 are 
suppressed by androgens in androgen-dependent cells 
with a luminal phenotype [30]. However it is known that 
miR-100 expression in human (androgen independent) 
corneal fibroblasts is significantly suppressed by 
synthetic glucocorticoid Dexamethasone (DEX) [49]. 
DEX treatment also induces resistance to radiation and 
cytotoxic therapy in multiple (androgen independent) 
human cancer types [50–52]. Our previous data showed 
that glucocorticoid receptor (GR/NR3C1) expression is 
higher in primary prostate normal and cancer stem cells, 
compared to CB cells from normal and cancer primary 
cultures (Supplement Figure S2D). Therefore, when CB 
populations were treated with DEX the expected lower 
expression of both miR-99a/miR-100, and a reciprocally 
increased expression of SMARCA5 and SMARCD1 
mRNA, compared with ethanol (EtOH) treated cells 
(Figure 6A, 6B) was observed. Treatment with 10 
nM DEX also increased SMARCA5 and SMARCD1 
protein levels in CB cells 72 h after treatment (Figure 
Figure 5: Suppression of miR-99a/100-induced efficient DNA repair in CB cells is not due to induction of epithelial–
mesenchymal transition or de-differentiation. A. Representative western blot analysis of epithelial-mesenchymal transition-
associated proteins E-cadherin (CDH1), fibronectin (FN1) and Vimentin (VIM) in CB cells transfected with control, miR-99a-inhibitor, and 
miR-100-inhibitor, for 3 days. B. FACS analysis for CD49b (ITGB2) and CD49f (ITGB6) expression of CB cells transfected with either 
control or miR-99a inhibitor for 3 days (n=3 PCa). C. mRNA levels of differentiation-associated genes (Nuclear factor kappa-light-chain-
enhancer of activated B cells 1 (NFkB1), DNA-binding protein inhibitor ID-2 (ID2), prominin 1 (PROM1), Sex determining region Y-box 
2 (SOX2), Homeobox protein Nkx-3.1 (NKX3.1), Wingless-Type MMTV Integration Site Family, Member 5A (WNT5a) and Pappalysin 
A (PAP)) after miR-99a-inhibitor transfection in CB cells, for 3 days, relative to control transfection. None of the changes were statistically 
significant (n = 2 BPH and 3 PCa, each sample in triplicate) were measured by qRT-PCR and normalized to RPLP0. D. Colony forming 
efficiency of miR-99a/100 inhibitor transfected CB cells (n=3 PCa). E. Wound healing assay miR-99a/100 inhibitor transfected CB cells 
after 48 h. Data are expressed as mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s ttest).
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Figure 6: Effects of miR-99a/100 on DNA repair processes are regulated by SMARCA5 and SMARCD1. A. qRT-PCR 
analysis of miR-99a and miR-100 expression in CB cells treated with R1881 or dexamethasone (DEX) for 72 h (n= 5 PCa). B. qRT-PCR 
analysis of SMARCA5 and SMARCD1 expression in CB cells treated with DEX for 72 h (n= 5 PCa). C. Representative western blot 
analysis of SMARCA5 and SMARCD1 in CB cells treated with R1881 or DEX for 72 h. D. Cell viability assay after 72 h of CB cells 
exposed to DEX for 72 h followed by irradiation (Gy 5, n=3 PCa). E. qRT-PCR analysis of miR-99a and miR-100 expression in total primary 
cell populations treated with Mifepristone for 72 h (n= 5 PCa). F. qRT-PCR analysis of SMARCA5 and SMARCD1 expression in total 
primary cell populations treated with Mifepristone for 72 h (n= 5 PCa). G. Cell viability assay after 72 h of total primary cell populations 
after exposure to DEX for 72 h followed by irradiation (Gy 5, n=5 PCa). H. Colony forming efficiency of primary prostate cells after being 
exposure to Mifepristone for 72 h followed by irradiation (Gy 5, n=5 PCa). I. Schematic representation of the hypothesis, which proposes 
a feedback loop between androgen receptor (AR)-miR99a/100-SMARCD1 and glucocorticoid receptor (GR)-miR99a/100-SMARCD1 in 
androgen dependent and androgen independent cells. Data are expressed as mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s ttest).
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6C). However, treatment of androgen-independent CB 
and PC3 cells, with the synthetic androgen R1881 (10 
nM), did not result in a change of miR-99a/miR-100 or 
SMARCA5 and SMARCD1 expression (Figure 6A, 6B, 
Supplementary Figure S3A), whereas LNCaP, an AR 
expressing PCa cell line demonstrated a downregulation 
of both miRNAs after R1881 treatment (Supplementary 
Figure S3B), confirming previous data [30]. Whilst in 
androgen-dependent LNCaP cells, treatment with the anti-
androgen Bicalutamide (BC) reverses the down-regulation 
of miR-99a/100, no BC effects were seen in androgen-
independent PC3 cells (Supplementary Figure S3A, S3B). 
Subsequently, when we measured the viability of DEX-
treated near-patient CB cells after irradiation, the DEX-
treated population contained 4 fold more viable cells after 
irradiation compared to the control population (Figure 
6D). Our results show that inhibition of miR-99a/miR-
100 via glucocorticoid treatment results in an increased 
DNA repair efficiency at least partly through regulation 
of the SMARCA5 and SMARCD1 proteins in androgen-
independent cells.
Inhibition of the glucocorticoid receptor 
downregulates miR-99a/100 expression levels
Having demonstrated that stimulation of the GR 
with DEX led to suppression of miR-99a/100 expression 
(Figure 6A, 6B), total cell populations of patient-derived 
prostate cells were treated with the GR antagonist 
Mifepristone at the clinically achievable concentration 
of 1 μM [53]. miR-99a/miR-100 were significantly 
upregulated in the treated samples (Figure 6E). qRT-PCR 
analysis of the miR-99a and miR-100 targets SMARCA5 
and SMARCD1 showed the expected decrease of both 
targets after Mifepristone treatment (Figure 6F). When 
Mifepristone treated cells were irradiated (5 Gy), cell 
viability showed no changes between Mifepristone and 
Dimethyl sulfoxide (DMSO) pre-treated cells (Figure 
6F), but a significant decrease in clonogenic potential was 
observed with mifepristone treatment, which was further 
reduced after irradiation (Figure 6G). These data revealed 
that miR-99a/100 are regulated by glucocorticoids 
and influence DNA repair efficiency by modulating 
SMARCA5 and SMARCD1 in androgen-independent 
primary PCa cells (Figure 6I), with particular activity 
within the highly clonogenic stem-like cells.
DISCUSSION
Recent studies have demonstrated that cells 
possessing a basal phenotype in the human prostate play 
an important role in tumor relapse and development of 
aggressive cancer [9, 54]. These cells represent less than 
1% of the overall tumor mass and are highly resistant 
to commonly used therapies in PCa [9]. miRNAs have 
been shown to play a key role in chemotherapeutic drug 
resistance, and we now show that miR-99a/miR-100 are 
downregulated in patients with CRPC compared with 
benign disease. Interestingly, the SC and CSC miRNA 
signatures were recapitulated in unfractionated CRPC 
samples, but not in treatment-naïve cancers. This is in 
agreement with other studies, which have shown that 
SC and CSC mRNA and miRNA signatures are similar 
to those of unfractionated CRPC [54–56]. Furthermore, 
patients with low levels of miR-99a/miR-100 are more 
susceptible to biochemical recurrence after treatment. 
Taken together, these data reveal the potential of the miR-
99 family as a marker for bad prognosis.
In our previous work we integrated miRNA-mRNA 
expression datasets and demonstrated that miR-99a/miR-
100 plays an essential role in DNA repair [25, 35]. In this 
study, using patient-derived cells, we have shown that 
inhibition of miR-99a/miR-100 prevents p53 dependent 
apoptosis in PCa cells after irradiation. Moreover, 
suppressed miR-99a/100 levels enable efficient relaxation 
of damaged chromatin by increasing histone acetylation 
and subsequently increasing the recruitment of DNA repair 
proteins, BRCA1 and RAD51. Using loss of function and 
rescue experiments, we now demonstrate that SMARCA5 
and SMARD1 are the primary mediators of the miR-
99a/100 driven pathway. This result agrees with previous 
findings by Mueller et al, who showed a role for the miR-
99 family in DNA repair [21].
We also noted that inhibition of miR-99a/100 (and 
overexpression of SMARCA5 and SMARCD1) resulted 
in small but significant increase in colony forming 
efficiency, but other stem cell markers remain statistically 
unchanged. Perhaps miR-99a/100 inhibition or expression 
of SMARCA5/SMARCD1 alone is required but not 
sufficient for de-differentiation. Previous data showed 
that concomitant overexpression of proteins such as EZH2 
along with SMARCA5 overexpression is needed for 
epithelial stem cell maintenance [57]. EZH2 has also been 
shown to be a critical regulator of stem cell functionality, 
radio-resistance, and prostate cancer aggressiveness [58–
60]. It is indeed possible that EZH2 and miR-99a/100 
can collaborate in regulating prostate cancer stem cell 
functionality and radiation-sensitivity.
Our results also show that PARP1, whose expression 
is essential for the miR-99a/100 driven DNA damage 
response, is an important component of this process. 
PARP1 is essential for the maintenance of genomic 
integrity, due to its roles in DNA repair, chromatin 
remodeling, and transcription factor regulation [61]. 
PARP inhibition has recently been shown, in a subset 
of PCa patients, to expand survival times and increase 
radiosensitivity in xenografts [62, 63]. Based on these 
findings, PARP inhibition seems plausible as a potential 
enhancer of radiation therapy in PCa. Our results show 
that in cells treated with esiRNA against PARP1 or 
with the non-selective PARP inhibitor nicotinamide, 
recruitment of the DNA repair protein SMARCA5 and, 
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to a smaller extent, SMARCD1 is inhibited. Inhibition 
of PARP ultimately interferes with the miR-99a/100-
SMARCA5/SMARCD1 axis and thus DNA repair. These 
results provide evidence of an important mechanism by 
which PARP1 inhibition can result in radiosensitization in 
human cancers.
However, studies in prostate and other cancer 
types, have also reported PARP inhibitor resistance as 
a result of EMT, which is often present in cancers that 
acquire resistance to treatment [64–66]. In general, EMT 
is described as reprogramming of terminally differentiated 
cells into more mesenchymal-type cells [67]. Since we 
saw no changes in the expression of EMT markers after 
miR-99a/100 inhibition, the mechanism behind the change 
in DNA damage response after inhibition of miR-99a or 
miR100 is not due to dedifferentiation/EMT.
Our data demonstrate that the expression of miR-
99a/100 is also regulated by GR control of the DNA 
damage response following irradiation. The exact 
mechanism by which GR influences miRNAs dosage has 
not yet been clarified, however it was previously shown 
that glucocorticoids could influence miRNA-processing 
enzymes [68]. Since miRNA are encoded in non-protein-
coding regions and often intronic elements, there is also 
the possibility that regulation can be influenced by a 
GR response element, as has been reported for miR-708 
[62]. miR-99a has been found in the lncRNA host gene 
MIR99AHG. Although MIR99AHG was shown to play 
an important role in leukaemia, little is known about its 
regulation [69]. miR-100 is located in an intronic area of 
the BH3-like motif-containing cell death inducer BLID, 
(https://omim.org/entry/615965) which has not been 
reported to be regulated by the GR and according to the 
Transcriptional Regulatory Element Database the gene has 
no cis- or trans- GR response elements (https://cb.utdallas.
edu/cgi-bin/TRED/tred.cgi?process=home). These data 
therefore suggest that there could be an indirect influence 
of GR on these miRNAs. Glucocorticoids are widely used 
with adjuvant chemotherapy to attenuate off target toxicity 
and nausea. However, usage of glucocorticoids remains 
controversial; On the one hand, reduction of negative 
side effects during therapy using glucocorticoids is quite 
successful, but there are increasing reports suggesting 
that glucocorticoids can counteract taxane-based 
therapies, induce therapy resistance and support growth 
of aggressive tumor phenotypes [70–73]. A recent study 
of GR inhibition demonstrated reversion of docetaxel 
resistance in PCa [74]. Docetaxel resistant cancer and 
metastatic CRPC share several features with CSCs [72, 
75, 76]. Our results show high expression of the GR in 
the CSC population, which has been shown to be highly 
chemo- and radio-therapy resistant, and therefore thought 
to play a role in tumor relapse [8, 9]. Here we show that 
pre-treatment with Dexamethasone or the GR inhibitor 
Mifepristone resulted in sensitivity changes of primary 
PCa to irradiation, by directly influencing the expression 
levels of miR-99a/100. These data not only implicate 
GR in resistance to RT in PCa cells, but also highlight 
the role of GR and miR99a/100 in the development of RT 
resistant tumors. However, due to the limited knowledge 
of interaction and regulation of noncoding RNAs and 
how they together contribute to disease, there remain 
many challenges before miRNA-based therapies can be 
realized in treatment approaches. In contrast, the indirect 
regulation of miRNA via already established and FDA-
approved therapies seems to be more promising. Since GR 
inhibitors in CRPC patients are well tolerated, the use of 
GR inhibitors would be an acceptable means of enhancing 
RT efficiency and may potentially be a way to reduce 
tumor relapse frequencies [77].
We have shown in multiple near-patient PCa 
samples that the two miR-99 family members miR-99a/
miR-100 play an important role in regulation of post-
irradiation DNA damage response (via SMARC proteins) 
in the rare tumor initiating CSC population. The miRNAs 
can be upregulated by inhibition of the glucocorticoid 
receptor prior to radiotherapy. Therefore a combination 
therapy of GR inhibitors with RT could potentially 
enhance the efficiency of RT in PCa.
MATERIALS AND METHODS
Culture of cell lines and primary prostate cells
The PCa cell lines 22Rv1, LNCaP, PC3, and Du-
145 were obtained from ATCC (Rockville, MD, USA) 
and where cultured as previously described [78]. Benign 
and cancerous primary prostate cells were cultured as 
described earlier [8, 10, 79]. Primary prostate cells were 
further fractionated into stem cell populations (SC, 
CD44+/α2β1integrin
hi/CD133+), transit amplifying (TA) 
populations (CD44+/α2β1integrin
hi/CD133-, TA), and 
committed basal populations (CB, CD44+/α2β1integrin
low/
CD133-) on the basis of the protocol published previously 
by Richardson et al [79].
Irradiation of cells
Cells were irradiated using a RS2000 X-Ray 
Biological Irradiator, containing a Comet MXR-165 
X-Ray Source (Rad-Source Technologies Inc., Suwanee, 
GA, USA). A dose of 2, 5, 10 and 60 Gy was administered 
with a dose rate of 0.02 or 0.08 Gy s−1.
Immunofluorescence
Immunocytochemistry was performed as previously 
described [8]. Antibodies used are listed in Supplementary 
Table S1.
Images were captured using a Nikon Eclipse TE300 
fluorescent microscope (Nikon, Surrey, UK) and were 
analyzed using Volocity software (Improvision, Perkin 
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Elmer, Waltham, MA, USA). Pseudo-coloring and picture 
overlay was performed with Velocity software.
Quantitative real-time PCR for mRNA
Total RNA was extracted from cells using Qiagen 
RNease mini Kit (Qiagen, Manchester, UK) according to 
the manufacturer’s protocol. RNA was reverse transcribed, 
using random hexamers (Life Technologies Ltd, Paisley, 
UK) and reverse transcriptase kit SuperScript III (Life 
Technologies Ltd, Paisley, UK).
qRT-PCR was conducted using TaqMan gene 
expression assays (Life Technologies Ltd, Paisley, 
UK) and the iTaq™ Universal Supermixes (Bio-Rad 
Laboratories Ltd, Hertfordshire, UK), according to 
the manufacturer’s protocol. Total RNA was extracted 
from cells using mirVana™ miRNA Isolation Kit 
(Life Technologies Ltd, Paisley, UK), according to the 
manufacturer’s protocol. miRNA was reverse transcribed, 
using miScript II RT Kit (Qiagen, Manchester, UK). qRT-
PCR for miRNAs was conducted using human specific 
miScript Primer Assays (Qiagen, Manchester, UK) and the 
miScript SYBR® Green PCR Kit (Qiagen, Manchester, 
UK), according to the manufacturer’s protocol. All 
reactions were carried out in triplicate on FrameStar® 
96, fully-skirted plate with black frame and white wells 
for qRT-PCR (4titude Limited, Surrey, UK) in an CFX96 
Touch™ Real-Time PCR Detection System (Bio-Rad 
Laboratories Ltd, Hertfordshire, UK). Expression values 
are presented relative to the endogenous control gene, 
RPLP0 for mRNA and U6 small nuclear 6 for miRNA.
esiRNA and miRNA inhibitor transfection
The miRNA inhibitors anti-hsa-miR-99a-5p 
miScript miRNA Inhibitor (miR99a-i), Anti-hsa-
miR-100-5p miScript miRNA Inhibitor (miR100-i) 
and the endo-ribonuclease prepared siRNA (esiRNA) 
esiPARP1, esiSMARCA5, esiSMARCD1 (Sigma-
Aldrich Company Ltd, Gillingham, UK) were transfected 
with Lipofectamine® RNAiMAX Transfection Reagent 
(Life Technologies Ltd, Paisley, UK) according to the 
manufacturer’s protocol.
Western blot
After the required treatments, cells were washed 
with PBS, followed by lysis in RIPA buffer, and the 
sample buffer for SDS–PAGE was added. The protein 
concentrations were determined using the Pierce™ BCA 
Protein Assay Kit (Life Technologies Ltd, Paisley, UK). 
20 μg protein per lane were separated by 10% SDS–PAGE 
and transferred to polyvinylidene difluoride membranes 
(Millipore, Billerica, MA, USA). Antibodies used were as 
follows listed in Supplementary Table S1.
Membranes were developed in a GeneGnome XRQ 
imaging system (Syngene, Cambridge, UK) with BM 
Chemiluminescence Western Blotting Substrate (POD) 
(Roche, Welwyn Garden City, UK).
Clonogenic recovery
Unsorted or CB cells isolated from primary prostate 
cultures were treated with either 10 nM Dexamethasone 
(Sigma-Aldrich Company Ltd, Gillingham, UK) dissolved 
in Ethanol, 1 μM Mifepristone (RU486) (Sigma-Aldrich 
Company Ltd, Gillingham, UK) dissolved in DMSO for 
3 days, and/or irradiated with 5 Gy. According to the 
different clonogenic potential of the different populations, 
100 unsorted or 300 CB cells were plated on to 35-mm 
collagen I-coated plates (BD Biocoat; BD biosciences) in 
the presence of irradiated mouse embryonic fibroblast cell 
line STO cells as feeder cells. Colonies were subsequently 
scored if they contained more than 32 cells (5 population 
doublings) usually between 14 to 28 days after treatment 
[80].
Flow cytometry
Cultured cells were trypsinised, resuspended in 
MACs buffer and incubated with antibodies to the Integrin 
α2 (MCA743PET AbD Serotec, Kidlington, UK) and 
integrin α6 CD49f (11–0495–80, eBioscience, San Diego, 
USA) for 20 min at 4 °C. Cells were then analyzed on 
a CyAn-ADP flow cytometer (Beckman Coulter, High 
Wycombe, UK) and data processed using Summit v4.3 
software (Beckman Coulter).
Live cell count
Collected cells were stained with Trypan Blue 
(Sigma-Aldrich Company Ltd, Gillingham, UK) and 
counted using a Neubauer’s haemocytometer.
Cell migration assay
Cells were plated in a 10-cm dish for 48 hours. A 
wound was created using a 1-ml pipette tip. The width of 
the wound at 0 and 24 hours was measured using Volocity 
software (Perkin Elmer, Waltham, MA, USA). The 
average (of 10 random points) was taken and the relative 
percentage wound closure at 24 hours with respect to the 
starting wound size was calculated.
Statistical analyses
GraphPad Prism 5 (GraphPad Software, La Jolla, 
CA, USA) was used for statistical analyses. Mann–
Whitney U or the Student’s t-test was used to determine 
if two sets of data were significantly different from each 
other. Correlation analysis was performed by the Pearson’s 
method. Data are presented as mean±standard deviation 
(SD) unless otherwise specified. All experiments were 
performed in at least 3 independent replications.
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